Interactions

Displaying 1 - 200 of 1240

ARV

Drug 2

Color Code

Drug 1 dose (field_drug_1_dose)

Drug doses

ID	Title	drug 1 Sort descending	drug 1 dose	drug 1 effect	drug 2	drug 2 dose	drug 2 effect	Clinical Effects	Color	Clinical Bottom Line	Management	Alt Agents
6281	Abacavir Methadone 666	Abacavir	600 mg BID	No significant change	Methadone	40 mg once daily; 90 mg once daily	Methadone clearance increased 22%	Potential for decreased methadone effects (e.g., withdrawal)	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose	Buprenorphine and naloxone
6282	Abacavir MMF, MPA 667	Abacavir	300 mg BID	No significant change	Mycophenolate	500 mg BID x 16 weeks			Green: Administer standard doses	Administer standard doses
6283	Abacavir Ethanol 668	Abacavir	600 mg once daily	Abacavir AUC increased 41%; half-life: increased 26%; Cmax increased 15%; T1 / 2 increased	Ethanol	0.7 g / kg body weight	No significant change		Green: Administer standard doses	Administer standard doses
6284	Abacavir 3TC 669	Abacavir	600 mg x 1 dose	No significant change	Lamivudine	150 mg x 1 dose	Lamivudine Cmax decreased 35%; AUC decreased 15%		Green: Administer standard doses	Administer standard doses
6285	Abacavir AZT, ZDV 670	Abacavir	600 mg x 1 dose	No significant change	Zidovudine	300 mg x 1 dose	Zidovudine Cmax decreased 20%; AUC no significant change		Green: Administer standard doses	Administer standard doses
6286	Abacavir AZT, ZDV 671	Abacavir	200 mg TID, 400 mg TID, 600 mg TID, 300 mg BID	Inconsistent effect across all dosing regimens; No effect on AUC with clinical abacavir dose of 300mg BID	Zidovudine	200 mg TID, 300 mg BID	No significant change		Green: Administer standard doses	Administer standard doses
6291	Emtricitabine AZT, ZDV 676	Emtricitabine	200 mg daily x 7 days	No significant change	Zidovudine	300 mg once daily x 7 days	Cmax increased 17%, AUC increased 13%		Green: Administer standard doses	Administer standard doses
6292	Emtricitabine AZT, ZDV 677	Emtricitabine	200 mg daily x 7 days	No significant change	Zidovudine	300 mg once daily x 7 days	Cmax increased 17%, AUC increased 13%		Green: Administer standard doses	Administer standard doses
6293	Emtricitabine AZT, ZDV 678	Emtricitabine	200 mg daily x 7 days	No significant change	Zidovudine	300 mg once daily x 7 days	Cmax increased 17%, AUC increased 13%		Green: Administer standard doses	Administer standard doses
6294	Emtricitabine AZT, ZDV 679	Emtricitabine	200 mg daily x 7 days	No significant change	Zidovudine	300 mg once daily x 7 days	Cmax increased 17%, AUC increased 13%		Green: Administer standard doses	Administer standard doses
6295	Emtricitabine AZT, ZDV 680	Emtricitabine	200 mg daily x 7 days	No significant change	Zidovudine	300 mg once daily x 7 days	Cmax increased 17%, AUC increased 13%		Green: Administer standard doses	Administer standard doses
6296	Emtricitabine AZT, ZDV 681	Emtricitabine	200 mg daily x 7 days	No significant change	Zidovudine	300 mg once daily x 7 days	Cmax increased 17%, AUC increased 13%		Green: Administer standard doses	Administer standard doses
6297	Emtricitabine AZT, ZDV 682	Emtricitabine	200 mg daily x 7 days	No significant change	Zidovudine	300 mg once daily x 7 days	Cmax increased 17%, AUC increased 13%		Green: Administer standard doses	Administer standard doses
6298	Emtricitabine AZT, ZDV 683	Emtricitabine	200 mg daily x 7 days	No significant change	Zidovudine	300 mg once daily x 7 days	Cmax increased 17%, AUC increased 13%		Green: Administer standard doses	Administer standard doses
6299	Emtricitabine TDF 684	Emtricitabine	200 mg daily x 7 days	Cmin increase 20%	Tenofovir Disoproxil Fumarate	300 mg once daily x 7 days	no significant		Green: Administer standard doses	Administer standard doses
6300	Emtricitabine TDF 685	Emtricitabine	200 mg daily x 7 days	Cmin increase 20%	Tenofovir Disoproxil Fumarate	300 mg once daily x 7 days	No significant change		Green: Administer standard doses	Administer standard doses
6301	Emtricitabine TDF 686	Emtricitabine	200 mg daily x 7 days	Cmin increase 20%	Tenofovir Disoproxil Fumarate	300 mg once daily x 7 days	No significant change		Green: Administer standard doses	Administer standard doses
6302	Emtricitabine TDF 687	Emtricitabine	200 mg daily x 7 days	Cmin increase 20%	Tenofovir Disoproxil Fumarate	300 mg once daily x 7 days	No significant change		Green: Administer standard doses	Administer standard doses
6287	Emtricitabine TDF 672	Emtricitabine	200 mg daily x 7 days	Cmin increase 20%	Tenofovir Disoproxil Fumarate	300 mg once daily x 7 days	AUC increased 13%, Cmax increased 17%		Green: Administer standard doses	Administer standard doses
6303	Emtricitabine TDF 688	Emtricitabine	200 mg daily x 7 days	Cmin increase 20%	Tenofovir Disoproxil Fumarate	300 mg once daily x 7 days	No significant change		Green: Administer standard doses	Administer standard doses
6288	Emtricitabine Famciclovir 673	Emtricitabine	200 mg x 1 dose	Cmax decreased 10%; AUC decreased 7%	Famciclovir	500 mg x 1 dose	Cmax decreased 7%; AUC decreased 9%		Green: Administer standard doses	Administer standard doses
6304	Emtricitabine TDF 689	Emtricitabine	200 mg daily x 7 days	Cmin increase 20%	Tenofovir Disoproxil Fumarate	300 mg once daily x 7 days	No significant change		Green: Administer standard doses	Administer standard doses
6289	Emtricitabine AZT, ZDV 674	Emtricitabine	200 mg daily x 7 days	No significant change	Zidovudine	300 mg once daily x 7 days	Cmax increased 17%, AUC increased 13%		Green: Administer standard doses	Administer standard doses
6305	Emtricitabine Famciclovir 690	Emtricitabine	201 mg x 1 dose	no significant change	Famciclovir	500 mg x 1 dose	no significant change		Green: Administer standard doses	Administer standard doses
6290	Emtricitabine AZT, ZDV 675	Emtricitabine	200 mg daily x 7 days	No significant change	Zidovudine	300 mg once daily x 7 days	Cmax increased 17%, AUC increased 13%		Green: Administer standard doses	Administer standard doses
6306	Emtricitabine Famciclovir 691	Emtricitabine	202 mg x 1 dose	no significant change	Famciclovir	500 mg x 1 dose	no significant change		Green: Administer standard doses	Administer standard doses
6307	Lamivudine TMP/SMX 692	Lamivudine	300 mg daily x 1 dose	Lamivudine AUC increased 44%	Trimethoprim / Sulfamethoxazole	160 mg / 800 mg daily x 5 days	Not studied	Potentially increased lamivudine adverse effects	Green: Administer standard doses	Administer standard doses
6308	Lamivudine G/P 693	Lamivudine	300 mg daily	No significant change	Glecaprevir / Pibrentasvir	300 mg / 120 mg daily	GLE AUC decrease 25%, PIB AUC decrease 28%		Green: Administer standard doses	Administer standard doses
6309	Lamivudine Adefovir 694	Lamivudine		Not studied	Adefovir	10 mg daily	No significant change		Green: Administer standard doses	Administer standard doses
6310	Lamivudine Interferon alfa 695	Lamivudine	100 mg daily	No significant change	Interferon alfa	10 MU three times weekly	No significant change		Green: Administer standard doses	Administer standard doses
6311	Lamivudine Buprenorphine / naloxone 696	Lamivudine	300 mg daily		Buprenorphine / naloxone	14 mg daily	No significant change		Green: Administer standard doses	Administer standard doses
6312	Lamivudine Entecavir 697	Lamivudine		No significant change	Entecavir		No significant change		Green: Administer standard doses	Administer standard doses
6313	Lamivudine Methadone 698	Lamivudine	150 mg lamivudine / 300 mg zidovudine (combination tablet)	Not studied	Methadone		No significant change		Green: Administer standard doses	Administer standard doses
6314	Lamivudine ATV 699	Lamivudine	150 mg BID with zidovudine 300 mg BID x 6 days	No significant change	Atazanavir	400 mg daily x 6 days	Not studied		Green: Administer standard doses	Administer standard doses
6315	Lamivudine Ribavirin 700	Lamivudine	150 mg BID	No significant change	Ribavirin	800 mg daily			Green: Administer standard doses	Administer standard doses
6316	Lamivudine Sorbitol 701	Lamivudine	300 mg daily	AUC decreased 20-44%	Sorbitol	3.2 - 13.4 grams daily	Not studied	Potentially decreased lamivudine efficacy	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider using alternative agents. Interaction studied with liquid formulation. If unable to avoid co-administration, monitor for virologic efficacy.
6323	Tenofovir alafenamide LDV/SOF 708	Tenofovir Alafenamide	25 mg once daily	Cmax increased 3 - 17%, AUC increased 27-32%	Ledipasvir / Sofosbuvir	90 / 400 mg once daily	Ledipasvir: Cmax increased 1%, AUC increased 2%, Cmin increased 2%; sofosbuvir: Cmax decreased 4%, AUC increased 5%; sofosbuvir metabolite: Cmax 8%, AUC increased 8%, Cmin increased 10%		Green: Administer standard doses	Administer standard doses
6339	Tenofovir alafenamide St. John's Wort (Hypericum perforatum) 724	Tenofovir Alafenamide		Not studied	St. John's Wort		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Contraindicated. Use alternative agents.
6324	Tenofovir alafenamide Midazolam 709	Tenofovir Alafenamide	25 mg once daily	Not studied	Midazolam	2.5mg once daily (PO); 1mg once daily (IV)	midazolam (2.5mg PO): Cmax increased 2%, AUC increased 12%; midazolam (1mg IV): Cmax decreased 1%, AUC increased 8%		Green: Administer standard doses	Administer standard doses
6340	Tenofovir alafenamide CBZ 725	Tenofovir Alafenamide	25 mg once daily	Cmax decreased 57%, AUC decreased 55%	Carbamazepine	300 mg BID	Not reported	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of TAF	Contraindicated. Use alternative agents.
6325	Tenofovir alafenamide EE/NGM 710	Tenofovir Alafenamide	25 mg once daily	Not studied	Ethinyl estradiol / Norgestimate	NGM 0.180 / 0.215 / 0.250mg once daily with EE 0.025mg once daily	Norgestromin: Cmax increased 17%, AUC increased 12%, Cmin increased 16%; norgestrel: Cmax increased 10%, AUC increased 9%, Cmin increased 11%; EE: Cmax increased 22%, AUC increased 11%, Cmin increased 2%		Green: Administer standard doses	Administer standard doses
6326	Tenofovir alafenamide LDV/SOF 711	Tenofovir Alafenamide	10 mg once daily	Cmax decreased 10%; AUC decreased 14%	Ledipasvir / Sofosbuvir	90 / 400 mg once daily	Not reported		Green: Administer standard doses	Administer standard doses
6327	Tenofovir alafenamide EFV 712	Tenofovir Alafenamide	TAF 40 mg once daily	Cmin decreased 22%, AUC decreased 14%	Efavirenz	600 mg once daily	Not studied		Green: Administer standard doses	Administer standard doses
6328	Tenofovir alafenamide SOF/VEL/VOX 713	Tenofovir Alafenamide	25 mg once daily	Cmax increased 28%, AUC increased 57%	Sofosbuvir / Velpatasvir / Voxilaprevir	400 / 100 / 100 + 100 once daily	Sofosbuvir Cmax increased 14%, AUC increased 9%. Velpatasvir Cmax decreased 4%, AUC decreased 4%, Cmin decreased 6%. Voxilaprevir Cmax decreased 10%, AUC decreased 9%, Cmin decreased 3%		Green: Administer standard doses	Administer standard doses
6329	Tenofovir alafenamide SOF/VEL/VOX 714	Tenofovir Alafenamide	10 mg once daily	Cmax decreased 21%; AUC decreased 7%	Sofosbuvir / Velpatasvir / Voxilaprevir	400 / 100 / 100mg + 100mg voxilaprevir once daily	Sofosbuvir Cmax increased 14%, AUC increased 9%. Velpatasvir Cmax decreased 4%, AUC decreased 4%, Cmin decreased 6%. Voxilaprevir Cmax decreased 10%, AUC decreased 9%, Cmin decreased 3%		Green: Administer standard doses	Administer standard doses
6330	Tenofovir alafenamide SOF/VEL 715	Tenofovir Alafenamide	10 mg once daily	Cmax decreased 20%, AUC decreased 13%	Sofosbuvir / Velpatasvir	400 / 100mg once daily	Sofosbuvir: Cmax increased 23%, AUC increased 37%; Sofosbuvir metabolite: Cmax increased 29%, AUC increased 48%, Cmin increased 58%; velpatasvir: Cmax increased 30%, AUC increased 50%, Cmin increased 60%		Green: Administer standard doses	Administer standard doses
6331	Tenofovir alafenamide Adefovir 716	Tenofovir Alafenamide		Not studied	Adefovir		Not studied	Potential for increased renal adverse effects	Red: Avoid combination	Do not coadminister: Potential for increased levels of TAF	Contraindicated. Use alternative agents.
6332	Tenofovir alafenamide RFB 717	Tenofovir Alafenamide		Not studied	Rifabutin		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Contraindicated. Use alternative agents.
6317	Tenofovir alafenamide DRV/r 702	Tenofovir Alafenamide	10 mg once daily	Cmax increased 42%, AUC increased 6%	Darunavir	800 / 100 mg once daily	Cmax decreased 1%, AUC increased 1%, Cmin increased 13%		Green: Administer standard doses	Administer standard doses
6333	Tenofovir alafenamide RIF 718	Tenofovir Alafenamide		Dosed once: AUC decreased 55%; dosed twice: AUC decreased 14%	Rifampin		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Contraindicated. Use alternative agents.
6318	Tenofovir alafenamide ATV 703	Tenofovir Alafenamide	10 mg once daily	Cmax increased 77%, AUC increased 91%	Atazanavir	300 mg + 100mg ritonavir once daily	Cmax decreased 2%, AUC decreased 1%		Green: Administer standard doses	Administer standard doses
6334	Tenofovir alafenamide Oxcarbazepine 719	Tenofovir Alafenamide		Not studied	Oxcarbazepine		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Contraindicated. Use alternative agents.
6319	Tenofovir alafenamide RPV 704	Tenofovir Alafenamide	25 mg once daily	Cmax increased 1%, AUC increased 1%	Rilpivirine	25 mg once daily	Cmax decreased 7%, AUC increased 1%, Cmin increased 13%		Green: Administer standard doses	Administer standard doses
6335	Tenofovir alafenamide Phenobarbital 720	Tenofovir Alafenamide		Not studied	Phenobarbital		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Contraindicated. Use alternative agents.
6320	Tenofovir alafenamide Sertraline 705	Tenofovir Alafenamide	10 mg once daily	AUC decreased 4%	Sertraline	50 mg once daily	Cmax increased 14%, AUC increased 9%		Green: Administer standard doses	Administer standard doses
6336	Tenofovir alafenamide Phenytoin 721	Tenofovir Alafenamide		Not studied	Phenytoin		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Contraindicated. Use alternative agents.
6321	Tenofovir alafenamide DTG 706	Tenofovir Alafenamide	10 mg once daily	Cmax increased 24%, AUC increased 19%	Dolutegravir	50 mg once daily	Cmax increased 15%, AUC increased 2%, Cmin increased 5%		Green: Administer standard doses	Administer standard doses
6337	Tenofovir alafenamide Primidone 722	Tenofovir Alafenamide		Not studied	Primidone		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Contraindicated. Use alternative agents.
6322	Tenofovir alafenamide DRV/c 707	Tenofovir Alafenamide	25 / 200 mg once daily	Cmax decreased 7%, AUC decreased 2%	Darunavir	800 / 150 mg once daily	Cmax increased 2%, AUC decreased 1%, Cmin decreased 3%		Green: Administer standard doses	Administer standard doses
6338	Tenofovir alafenamide RPT 723	Tenofovir Alafenamide		Not studied	Rifapentine		Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of TAF	Contraindicated. Use alternative agents.
6355	Tenofovir disoproxil fumarate ABC 740	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Abacavir	300 mg x 1	No significant change		Green: Administer standard doses	Administer standard doses
6356	Tenofovir disoproxil fumarate Methadone 741	Tenofovir Disoproxil Fumarate	300 mg once daily	Not studied	Methadone	40-110 mg once daily (individual patients on stable dose)	No significant change		Green: Administer standard doses	Administer standard doses
6341	Tenofovir disoproxil fumarate ATV 726	Tenofovir Disoproxil Fumarate	300 mg once daily	Cmax increase 39%, AUC increase 55%, Cmin increase 70%	Atazanavir	400 mg once daily with 100 mg ritonavir daily	Cmax increase 31%, AUC increase 38%, Cmin increase 33%	Increased atazanavir and tenofovir effects	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	Do not coadminister with unboosted atazanavir (400 mg). Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. If coadministering atazanavir, ritonavir, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg (plus 100 mg ritonavir).
6357	Tenofovir disoproxil fumarate DTG 742	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Dolutegravir	50 mg once daily	No significant change		Green: Administer standard doses	Administer standard doses
6342	Tenofovir disoproxil fumarate ATV 727	Tenofovir Disoproxil Fumarate	300 mg once daily with a light meal	Cmax increase 14%, AUC increase 24%, Cmin increase 22%	Atazanavir	400 mg once daily with a light meal	Cmax decrease 21%, AUC decrease 25%, Cmin decrease 40%	Increased tenofovir effects, decreased atazanavir effects	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	Do not coadminister with unboosted atazanavir (400 mg). Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. If coadministering atazanavir, ritonavir, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg (plus 100 mg ritonavir).
6358	Tenofovir disoproxil fumarate Daclatasvir 743	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Daclatasvir	60 mg once daily	No significant change		Green: Administer standard doses	Administer standard doses
6343	Tenofovir disoproxil fumarate ATV 728	Tenofovir Disoproxil Fumarate	300 mg once daily, separated 12 hours away from atazanavir / ritonavir	Cmax increase 34%, AUC increase 37%, Cmin increase 29%	Atazanavir	300 mg once daily with 100 mg ritonavir daily	Cmax decrease 28%, AUC decrease 25%, Cmin decrease 23%	Increased tenofovir effects, decreased atazanavir effects	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	Do not coadminister with unboosted atazanavir (400 mg). Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. If coadministering atazanavir, ritonavir, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg (plus 100 mg ritonavir).
6359	Tenofovir disoproxil fumarate EFV 744	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Efavirenz	600 mg once daily	No significant change		Green: Administer standard doses	Administer standard doses
6344	Tenofovir disoproxil fumarate ATV/c 729	Tenofovir Disoproxil Fumarate		Not studied (may increase TDF levels)	Atazanavir / Cobicistat		Not studied (may decrease atazanavir levels)	Potentially increased risk of TDF adverse effects and decreased efficacy of atazanavir	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	If coadministering atazanavir, cobicistat, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg
6360	Tenofovir disoproxil fumarate RIF 745	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Rifampin	600 mg once daily	No significant change		Green: Administer standard doses	Administer standard doses
6345	Tenofovir disoproxil fumarate RPV 730	Tenofovir Disoproxil Fumarate	300 mg once daily	Cmax increase 19%, AUC increase 23%, Cmin increase 24%	Rilpivirine	150 mg once daily	No significant change	Potentially increased risk of TDF adverse effects	Green: Administer standard doses	Administer standard doses	Use recommended dose of rilpivirine 25 mg
6361	Tenofovir disoproxil fumarate Ribavirin 746	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Ribavirin	800 mg x 1	No significant change		Green: Administer standard doses	Administer standard doses
6346	Tenofovir disoproxil fumarate G/P 731	Tenofovir Disoproxil Fumarate		Not studied (may increase TDF levels)	Glecaprevir / Pibrentasvir		Not studied	(when given with EFV / FTC)	Green: Administer standard doses	Administer standard doses
6362	Tenofovir disoproxil fumarate Adefovir 747	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Adefovir	10 mg once daily	No significant change	Potential for increased risk of TDF adverse effects and / or increased concentration of other renally eliminated drugs	Red: Avoid combination	Do not coadminister: Potential for increased levels of TDF	Avoid combination and use alternative agents
6347	Tenofovir disoproxil fumarate SOF 732	Tenofovir Disoproxil Fumarate	300 mg once daily	Cmax increase 25%	Sofosbuvir	400 mg x 1	Cmax decrease 19%		Green: Administer standard doses	Administer standard doses
6363	Tenofovir disoproxil fumarate Ganciclovir 748	Tenofovir Disoproxil Fumarate		Not studied (may increase TDF levels)	Ganciclovir		Not studied (may increase ganciclovir levels)	Potential for increased risk of TDF and / or ganciclovir adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for adverse effects
6348	Tenofovir disoproxil fumarate ETR 733	Tenofovir Disoproxil Fumarate	300 mg once daily	Cmax increase 15%, AUC increase 15%, Cmin increase 19%	Etravirine	200 mg BID	Cmax decrease 19%, AUC decrease 19%, Cmin decrease 18%		Green: Administer standard doses	Administer standard doses
6364	Tenofovir disoproxil fumarate Valganciclovir 749	Tenofovir Disoproxil Fumarate		Not studied (may increase TDF levels)	Valganciclovir		Not studied (may increase ganciclovir levels)	Potential for increased risk of TDF and / or ganciclovir adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for adverse effects
6349	Tenofovir disoproxil fumarate 3TC 734	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Lamivudine	150 mg BID	Cmax decrease 24%		Green: Administer standard doses	Administer standard doses
6365	Tenofovir disoproxil fumarate SOF/VEL 750	Tenofovir Disoproxil Fumarate	300 mg once daily	Cmax increased 36%; AUC increased 35%; Cmin increased 45%	Sofosbuvir / Velpatasvir	400 / 100mg once daily	Not studied	Potentially increased risk of TDF adverse effects (e.g. renal function decline)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for TDF adverse effects
6350	Tenofovir disoproxil fumarate RAL 735	Tenofovir Disoproxil Fumarate	300 mg once daily	Cmax decrease 23%, AUC decrease 10%, Cmin decrease 13%	Raltegravir	400 mg BID	Cmax increase 64%, AUC increase 49%		Green: Administer standard doses	Administer standard doses
6366	Tenofovir disoproxil fumarate SOF/VEL/VOX 751	Tenofovir Disoproxil Fumarate		Increase AUC 30-80% when given with various ARV containing TDF	Sofosbuvir / Velpatasvir / Voxilaprevir		Not studied	Potentially increased risk of TDF adverse effects (e.g. renal function decline)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for TDF adverse effects
6351	Tenofovir disoproxil fumarate Entecavir 736	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Entecavir	1 mg once daily	No significant change		Green: Administer standard doses	Administer standard doses
6367	Tenofovir disoproxil fumarate DRV 752	Tenofovir Disoproxil Fumarate	300 mg once daily	Cmax increase 24%, AUC increase 22%, Cmin increase 37%	Darunavir	300 mg BID with ritonavir 100 mg BID	Cmax increase 16%, AUC increase 21%, Cmin increase 24%	Increased risk of TDF and / or darunavir adverse effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for TDF adverse effects (e.g. renal function decline)
6352	Tenofovir disoproxil fumarate EE/NGM 737	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Ethinyl estradiol / Norgestimate	1 tab daily	No significant change		Green: Administer standard doses	Administer standard doses
6368	Tenofovir disoproxil fumarate LDV/SOF 753	Tenofovir Disoproxil Fumarate	300 mg once daily	AUC increase 40%-98%, Cmin increase 55-80% when TDF coadministered with rilpivirine and efavirenz or various PIs, INSTIs, and NNRTIs	Ledipasvir / Sofosbuvir	90 / 400 mg once daily	Not studied	Increased risk of TDF adverse effects (e.g. renal function decline)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering, monitor for TDF adverse effects. Avoid use if CrCl >60 ml / min.
6353	Tenofovir disoproxil fumarate Buprenorphine / naloxone 738	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Buprenorphine / naloxone	14-16 mg once daily	No significant change		Green: Administer standard doses	Administer standard doses
6354	Tenofovir disoproxil fumarate FTC 739	Tenofovir Disoproxil Fumarate	300 mg once daily	No significant change	Emtricitabine	200 mg once daily	No significant change		Green: Administer standard doses	Administer standard doses
5971	Doravirine RFB 356	Doravirine	100 mg x 1	AUC decreased 50%; Cmin decreased 68%	Rifabutin	300 mg daily	Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Contraindicated. Use alternative agents. If discontinuing the rifamycin, at least a 4 week cessation period is recommended prior to beginning doravirine.
5972	Doravirine RIF 357	Doravirine	100 mg x 1	AUC decreased 88%; Cmax decreased 57%, Cmin decreased 97%	Rifampin	600 mg daily	Not studied	Potential decrease in antiretroviral efficacy.	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Contraindicated. Use alternative agents. If discontinuing the rifamycin, at least a 4 week cessation period is recommended prior to beginning doravirine.
5973	Doravirine EFV 358	Doravirine	100 mg	AUC decreased 32%; Cmax decreased 14%; C24 decreased 50%	Efavirenz	600 mg daily x 14 days	Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Do not coadminister. Use alternative agents.
5974	Doravirine EFV 359	Doravirine	100 mg x 1	AUC decreased 62%; Cmax decreased 35%; C24 decreased 85%	Efavirenz	600 mg x 1	Not studied	Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Reduced levels of doravirine	Do not coadminister. Use alternative agents.
5959	Doravirine Omeprazole 344	Doravirine	100 mg x 1	AUC decreased 17%; Cmin decreased 16%	Omeprazole			Potential decrease in antiretroviral efficacy.	Green: Administer standard doses	Administer standard doses
5960	Doravirine RTV 345	Doravirine	50 mg x 1	AUC increased to 354%; Cmax increased by 31%; C24 increased to 291%	Ritonavir	100 mg BID	Not studied	Potential for increased doravirine adverse effects	Green: Administer standard doses	Administer standard doses	No dose adjustment necessary. Monitor for doravirine adverse effects.
5961	Doravirine Ketoconazole 346	Doravirine	100 mg x 1	AUC increased to 306%; Cmax increased by 25%; C24 increased to 275%	Ketoconazole	400 mg daily	Not studied	Potential for increased doravirine adverse effects	Green: Administer standard doses	Administer standard doses	No dose adjustment necessary. Monitor for doravirine adverse effects.
5962	Doravirine Carbamazepine 347	Doravirine			Carbamazepine			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Contraindicated. Use alternative agents. If discontinuing carbamazepine, a minimum 4 week cessation period is recommended prior to initiating doravirine.
5963	Doravirine Enzalutamide 348	Doravirine			Enzalutamide			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Contraindicated. Use alternative agents. If discontinuing enzalutamide, a minimum 4 week cessation period is recommended prior to initiating doravirine.
5964	Doravirine Mitotane 349	Doravirine			Mitotane			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Contraindicated. Use alternative agents. If discontinuing mitotane, a minimum 4 week cessation period is recommended prior to initiating doravirine.
5965	Doravirine Oxcarbazepine 350	Doravirine			Oxcarbazepine			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Contraindicated. Use alternative agents. If discontinuing oxcarbazepine, a minimum 4 week cessation period is recommended prior to initiating doravirine.
5966	Doravirine Phenobarbital 351	Doravirine			Phenobarbital			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Contraindicated. Use alternative agents. If discontinuing phenobarbital, a minimum 4 week cessation period is recommended prior to initiating doravirine.
5967	Doravirine Phenytoin 352	Doravirine			Phenytoin			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Contraindicated. Use alternative agents. If discontinuing phenytoin, a minimum 4 week cessation period is recommended prior to initiating doravirine.
5968	Doravirine St. John's Wort (Hypericum perforatum) 353	Doravirine			St. John's Wort			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Contraindicated. Use alternative agents. If discontinuing St. John's Wort, a minimum 4 week cessation period is recommended prior to initiating doravirine.
5969	Doravirine ETR 354	Doravirine			Etravirine			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Do not coadminister. Use alternative agents.
5970	Doravirine NVP 355	Doravirine			Nevirapine			Potential decrease in antiretroviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of doravirine	Do not coadminister. Use alternative agents.
5987	Efavirenz RFB 372	Efavirenz	600 mg x 14 days	No significant change	Rifabutin	300 mg daily x 14 days	Rifabutin AUC decreased 38%; Cmax decreased 32%	Decreased rifabutin effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
6003	Efavirenz Diltiazem 388	Efavirenz	600 mg daily x 14 days	No significant change	Diltiazem	240 mg daily x 21 days	Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63%	Decreased diltiazem effects	Green: Administer standard doses	Administer standard doses	Monitor diltiazem efficacy and to titrate to clinical effect
6019	Efavirenz Buprenorphine / naloxone 404	Efavirenz	600 mg daily x 15 days	No significant change	Buprenorphine / naloxone	stable dose for at least 2 weeks	Buprenorphine AUC decreased 49%; Cmax decreased 45%, Cmin decreased 50%; half-life: decreased 29%	Possible decreased buprenorphine effects	Green: Administer standard doses	Administer standard doses	Monitor for signs and symptoms of opioid withdrawal; some patients may need an increase in the buprenorphine dose, though study patients did not go into opioid withdrawal
6035	Efavirenz Cetirizine 420	Efavirenz	600 mg x 10 days	No significant change	Cetirizine	10 mg x 1 dose	Cetirizine Cmax decreased 24%		Green: Administer standard doses	Administer standard doses
6051	Efavirenz ATV 436	Efavirenz	600 mg daily 2 hours after atazanavir and ritonavir d 7-20		Atazanavir	400 mg daily d 1-6, then 300 mg daily days 7_-20 with ritonavir 100 mg daily	Atazanavir auc increased 39%, Cmax increased 48%, Cmin increased 14%.	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6067	Efavirenz Lumateperone 452	Efavirenz			Lumateperone			Decreased Lumateperon levels	Red: Avoid combination	Do not coadminister: Reduced levels of lumateperon	Avoid combination and use alternative agents
6083	Efavirenz Saquinavir 468	Efavirenz	600 mg daily for 10 days		Saquinavir	1200 mg every 8 hours for 10 days	AUC decreased 62%, Cmin decreased 56%, Cmax decreased %50	Potential loss of antiviral efficacy	Red: Avoid combination	Minimal data to guide interaction, weigh risks and benefits of using this combination	Use alternative agents
6099	Efavirenz Ticagrelor 484	Efavirenz			Ticagrelor			Possible decreased ticagrelor levels	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents
6115	Efavirenz Warfarin 500	Efavirenz		Not studied	Warfarin		Not studied (may increase or decrease warfarin levels)	Increased or decreased warfarin effects (altered INR, increased risk of bleeding or clotting)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
5988	Efavirenz RFB 373	Efavirenz	600 mg x 14 days	No significant change	Rifabutin	300 mg daily x 14 days	Rifabutin AUC decreased 38%; Cmax decreased 32%; Cmin decreased 45%	Decreased rifabutin effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
6004	Efavirenz Diltiazem 389	Efavirenz	600 mg daily x 14 days	No significant change	Diltiazem	240 mg daily x 21 days	Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63%	Decreased diltiazem effects	Green: Administer standard doses	Administer standard doses	Monitor diltiazem efficacy and to titrate to clinical effect
6020	Efavirenz Atorvastatin 405	Efavirenz	600 mg daily x 15 days	No significant change	Atorvastatin	10 mg daily x 4 days	Atorvastatin AUC decreased 43%, Cmax decreased %14, cmin decreased 69% Atorvastatin and metabolites AUC decreased 32%	Decreased lipid effects	Green: Administer standard doses	Administer standard doses	Monitor for statin efficacy. May need to increase atorvastatin dose
6036	Efavirenz Lorazepam 421	Efavirenz	600 mg x 10 days		Lorazepam	2 mg x 1 dose	Lorazepam AUC no significant change; Cmax increased 16%		Green: Administer standard doses	Administer standard doses
6052	Efavirenz ATV 437	Efavirenz	600 mg daily 2 hours after atazanavir and ritonavir d 7-20		Atazanavir	400 mg daily d 1-6, then 300 mg daily days 7_-20 with ritonavir 100 mg daily	Atazanavir auc increased 39%, Cmax increased 48%, Cmin increased 48%.	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6068	Efavirenz G/P 453	Efavirenz			Glecaprevir / Pibrentasvir			decreased pibrenatasvir / glecaprevir effects	Red: Avoid combination	Do not coadminister: Reduced levels of Pibrenatasvir / Glecaprevir	Contraindicated. Use alternative agents.
6084	Efavirenz Saquinavir 469	Efavirenz	600 mg daily for 10 days		Saquinavir	1200 mg every 8 hours for 10 days	AUC decreased 62%, Cmin decreased 56%, Cmax decreased %50	Potential loss of antiviral efficacy	Red: Avoid combination	Minimal data to guide interaction, weigh risks and benefits of using this combination	Use alternative agents
6100	Efavirenz Phenytoin 485	Efavirenz		Not studied (may decrease efavirenz levels)	Phenytoin		Not studied (may decrease phenytoin levels)	Decreased efavirenz and phenytoin effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents. If coadministering, \monitor phenytoin levels and adjust as indicated	Gabapentin Lamotrigine Tiagabine Topiramate
6116	Efavirenz Warfarin 501	Efavirenz		Not studied	Warfarin		Not studied (may increase or decrease warfarin levels)	Increased or decreased warfarin effects (altered INR, increased risk of bleeding or clotting)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	If coadministering monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
5989	Efavirenz RFB 374	Efavirenz	600 mg x 14 days	No significant change	Rifabutin	300 mg daily x 14 days	Rifabutin AUC decreased 38%; Cmax decreased 32%; Cmin decreased 45%	Decreased rifabutin effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
6005	Efavirenz Diltiazem 390	Efavirenz	600 mg daily x 15 days	No significant change	Diltiazem	240 mg daily x 21 days	Diltiazem AUC decreased 69%; Cmax decreased 60%; Cmin decreased 63%	Decreased diltiazem effects	Green: Administer standard doses	Administer standard doses	Monitor diltiazem efficacy and to titrate to clinical effect
6021	Efavirenz Atorvastatin 406	Efavirenz	600 mg daily on days 4-18	No significant change	Atorvastatin	10 mg daily on days 0-3 and 15-18	Atorvastatin AUC decreased 43%; Atorvastatin and metabolites AUC decreased 34%	Decreased lipid effects	Green: Administer standard doses	Administer standard doses	Monitor for statin efficacy. May need to increase atorvastatin dose
6037	Efavirenz Lorazepam 422	Efavirenz	600 mg x 10 days		Lorazepam	2 mg x 1 dose	Lorazepam AUC no significant change; Cmax increased 16%		Green: Administer standard doses	Administer standard doses
6053	Efavirenz ATV 438	Efavirenz	600 mg daily days 11-24		Atazanavir	300 mg daily / ritonavir 100 mg daily days 1-10 then 400 mg daily / ritonavir 100 mg daily days 11-24	Atazanavir Cmin decreased 42%, Cmax increased 17%	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6069	Efavirenz Pimavanserin 454	Efavirenz			Pimavanserin			Decreased pimavanserin levels	Red: Avoid combination	Do not coadminister: Reduced levels of pimavanserin	Avoid combination and use alternative agents
6085	Efavirenz Artemether / Lumefantrine 470	Efavirenz	600 mg daily x 26 days		Artemether / Lumefantrine	artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days	Aremether AUC decreased 51%, Cmax decreased 21% Lumefantrine AUC decreased 21%	Potentially compromised antimalarial activity	Orange: Minimal data to guide interaction	Consider using alternative agents	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
6101	Efavirenz Phenytoin 486	Efavirenz		Not studied (may decrease efavirenz levels)	Phenytoin		Not studied (may decrease phenytoin levels)	Decreased efavirenz and phenytoin effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents. If coadministering, \monitor phenytoin levels and adjust as indicated
6117	Efavirenz NVP 502	Efavirenz	600 mg daily	Efavirenz AUC decreased 22%; Cmin decreased 36%	Nevirapine	200 mg daily x 2 weeks, then 400 mg daily	No significant change	Decreased efavirenz effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Monitor and adjust therapy as indicated; may consider increasing efavirenz to 800 mg daily
5990	Efavirenz RFB 375	Efavirenz	600 mg daily	Not studied	Rifabutin	300 mg or 450 mg twice weekly	On 300 mg rifabutin twice weekly, rifabutin level 2 hours after dose: no significant change; rifabutin level 6 hours post dose: decreased 27%; on 450 mg twice weekly, rifabutin level 2 hours post dose: no significant change; rifabutin level 6 hours post dose: decreased 58%(all values compared to rifabutin alone)	Potential decreased rifabutin effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
6006	Efavirenz Diltiazem 391	Efavirenz	600 mg daily x 28 days	EFV AUC increased 11%, Cmax increased %16, Cmin increased 13%	Diltiazem	240 mg daily x 14 days		Decreased diltiazem effects	Green: Administer standard doses	Administer standard doses	Monitor diltiazem efficacy and to titrate to clinical effect
6022	Efavirenz Atorvastatin 407	Efavirenz	600 mg daily x 15 days	No significant change	Atorvastatin	10 mg daily x 5 days	Atorvastatin AUC decreased 43%; Cmax decreased 14%, Cmin decreased 69%. Atorvastatin and metabolites AUC decreased 32%, Cmin decreased 48%, Cmax decreased 15%	Decreased lipid effects	Green: Administer standard doses	Administer standard doses	Monitor for statin efficacy. May need to increase atorvastatin dose
6038	Efavirenz NFV 423	Efavirenz	600 mg QHS		Nelfinavir	750 mg TID	Nelfinavir clearance: no significant changeM8 clearance: increased 43%		Green: Administer standard doses	Administer standard doses
6054	Efavirenz ATV 439	Efavirenz	600 mg daily days 11-24		Atazanavir	300 mg daily / ritonavir 100 mg daily days 1-10 then 400 mg daily / ritonavir 100 mg daily days 11-24	Atazanavir Cmin decreased 43%, Cmax increased 17%	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6070	Efavirenz EE/NGM 455	Efavirenz	600 mg QHS		Ethinyl estradiol / Norgestimate	0.025 mg ethinyl estradiol / 0.25 mg norgestimate	Ethinyl estradiol: no significant change; Norgestromin AUC decreased 64%; Cmax decreased 46%; Cmin decrased 82%	Decreased effects of ethinyl estradiol and norgestimate	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Use alternative contraceptive method
6086	Efavirenz Artemether / Lumefantrine 471	Efavirenz	600 mg daily x 26 days	EFV AUC decreased 17%	Artemether / Lumefantrine	artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days	Aremether AUC decreased 51%, Cmax decreased 21% Lumefantrine AUC decreased 21%.	Potentially compromised antimalarial activity	Orange: Minimal data to guide interaction	Consider using alternative agents	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
6102	Efavirenz Phenobarbital 487	Efavirenz		Not studied (may decrease levels)	Phenobarbital		Not studied	Decreased efavirenz effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents. If coadministering, monitor phenobarbital levels and adjust as indicated	Gabapentin Lamotrigine Tiagabine Topiramate
6118	Efavirenz Midazolam 503	Efavirenz		Not studied	Midazolam		Not studied (may increase midazolam levels)	Increased midazolam effects (eg, increased sedation, confusion, respiratory depression)	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation. Chronic midazolam administration (oral or intravenous) should be avoided.	Lorazepam
5975	Efavirenz Fluvastatin 360	Efavirenz			Fluvastatin			Potential for increased levels of fluvastatin	Yellow: Adjust dosing	adjust dosing to avoid increased levels of fluvastatin
5991	Efavirenz RFB 376	Efavirenz	600 mg daily	Not studied	Rifabutin	600 mg twice weekly	Rifabutin AUC no significant change; Cmax no significant change (when compared to rifabutin 300 mg twice weekly without efavirenz)		Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of rifabutin	Increase rifabutin to 450-600 mg daily. May use rifabutin 300 mg three times weekly if not coadministered with a protease inhibitor
6007	Efavirenz RIF 392	Efavirenz	600 mg daily x 14 days	Efavirenz AUC decreased 22%; Cmax decreased 24%; Cmin decreased 25%	Rifampin	600 mg daily x 14 days	No significant change	Decreased efavirenz effects	Green: Administer standard doses	Administer standard doses	Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily for patient's weighing 50 kg or more when used with rifampin	Rifabutin
6023	Efavirenz Linagliptin 408	Efavirenz			Linagliptin			Possible decrease in antihyperglycemic effects	Green: Administer standard doses	Administer standard doses	Monitor glycemic control
6039	Efavirenz 3TC 424	Efavirenz	600 mg x 14 days	Not studied	Lamivudine	150 mg Q12H x 14 days	No significant change		Green: Administer standard doses	Administer standard doses
6055	Efavirenz ATV/c 440	Efavirenz		Not studied	Atazanavir / Cobicistat		Not studied (may decrease atazanavir and cobicistat levels)	Potential loss of antiviral efficacy	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Use alternative agents
6071	Efavirenz EE/NGM 456	Efavirenz	600 mg QHS		Ethinyl estradiol / Norgestimate	0.035 mg ethinyl estradiol / 0.25 mg norgestimate x 14 days	Ethinyl estradiol: no significant change; Norgestromin AUC decreased 64%; Cmax decreased 46%; Cmin decrased 82%	Decreased effects of ethinyl estradiol and norgestimate	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Use alternative contraceptive method
6087	Efavirenz Artemether / Lumefantrine 472	Efavirenz	600 mg daily x 26 days		Artemether / Lumefantrine	artemether 20mg / lumefantrine 120 mg 4 tablets / dose for 6 doses total in 3 days	Aremether AUC decreased 79%, Lumefantrine AUC decreased 30%-56%.	Potentially compromised antimalarial activity	Orange: Minimal data to guide interaction	Consider using alternative agents	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
6103	Efavirenz Phenobarbital 488	Efavirenz		Not studied (may decrease levels)	Phenobarbital		Not studied	Decreased efavirenz effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents. If coadministering, monitor phenobarbital levels and adjust as indicated
6119	Efavirenz CBZ 504	Efavirenz	600 mg daily x 14 days	Not studied (may decrease efavirenz levels)	Carbamazepine	200 mg daily x 3 days, 200 mg BID x 3 days, 400 mg daily for 20 days.	Carbmazepine AUC decreased 27%, Cmin 35%, Cmax decreased 20%	Decreased efavirenz and carbamazepine effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use alternative agents. If coadministering, monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
5976	Efavirenz Daclatasvir 361	Efavirenz	600 mg daily		Daclatasvir	120 mg daily	Daclatasvir Cmax increased 67%; AUC increased 37%.	Potential loss of anti-HCV efficacy	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of daclatasvir	Increase daclatasvir dose to 90 mg daily.
5992	Efavirenz Simvastatin 377	Efavirenz	600 mg daily on days 4-18	No significant change	Simvastatin	40 mg daily on days 0-3 and 15-18	Simvastatin AUC decreased 58%	Decreased lipid effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of simvastatin	Monitor statin efficacy. May need to increase simvastatin dose
6008	Efavirenz RIF 393	Efavirenz	600 mg x 7 days	Efavirenz AUC decreased 26%; Cmax decreased 20%	Rifampin	600 mg x 7 days		Decreased efavirenz effects	Green: Administer standard doses	Administer standard doses	Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily when used with rifampin	Rifabutin
6024	Efavirenz RTV 409	Efavirenz	600 mg x 10 days	Efavirenz AUC increased 21%; Cmax no significant change	Ritonavir	500 mg Q12H x 8 days	Ritonavir AUC increased 18% after AM dose; Cmax increased 24% after AM dose; AUC no significant change after PM dose; Cmax no significant change after PM dose	Increased efavirenz and ritonavir effects	Green: Administer standard doses	Administer standard doses
6040	Efavirenz Valproic acid 425	Efavirenz	600 mg daily	Efavirenz Cmin no significant change; Cmax no significant change; AUC no significant change; half-life: decreased 22%	Valproic Acid	250 mg BID x 7 days	No significant change		Green: Administer standard doses	Administer standard doses
6056	Efavirenz St. John's Wort (Hypericum perforatum) 441	Efavirenz		Not studied (may decrease efavirenz levels)	St. John's Wort		Not studied	Decreased efavirenz effects	Red: Avoid combination	Do not coadminister: Potential for reduced levels of efavirenz	Contraindicated. Use alternative agents.
6072	Efavirenz EE/NGM 457	Efavirenz	600 mg daily for 14 days		Ethinyl estradiol / Norgestimate	0.035 mg ethinyl estradiol / 0.25 mg norgestimate x 14 days	Ethinyl estradiol: no significant change; Norgestromin AUC decreased 64%; Cmax decreased 46%; Cmin decreased 82%	Decreased effects of ethinyl estradiol and norgestimate	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Use alternative contraceptive method
6088	Efavirenz Atovaquone 473	Efavirenz	600 mg QHS		Atovaquone	250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43%	Potentially compromised antimalarial activity	Orange: Minimal data to guide interaction	Consider using alternative agents	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
6104	Efavirenz Phenobarbital 489	Efavirenz			Phenobarbital		Not studied	Decreased efavirenz effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents. If coadministering, monitor phenobarbital levels and adjust as indicated
6120	Efavirenz CBZ 505	Efavirenz	600 mg daily x 14 days	Not studied (may decrease efavirenz levels)	Carbamazepine	200 mg daily x 3 days, 200 mg BID x 3 days, 400 mg daily for 20 days.	Carbmazepine AUC decreased 27%, Cmin decreased 35%, Cmax decreased 20%	Decreased efavirenz and carbamazepine effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use alternative agents. If coadministering, monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
5977	Efavirenz DTG 362	Efavirenz	600 mg daily		Dolutegravir	50 mg daily	Dolutegravir AUC decreased 57%; Cmin decreased 75%	Potentially reduced dolutegravir effectiveness	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of dolutegravir	If no INSTI resistance, increase dolutegravir dosage to 50 mg BID. If known or clinically suspected INSTI resistance, use alternative combination
5993	Efavirenz Simvastatin 378	Efavirenz	600 mg x 15 days	No significant change	Simvastatin	40 mg daily x 4 days	Simvastatin AUC decreased 68%; Cmax decreased 72%; Cmin decreased 45%	Decreased simvastatin effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of simvastatin	Monitor statin efficacy. May need to increase simvastatin dose
6009	Efavirenz RIF 394	Efavirenz			Rifampin			Decreased efavirenz effects	Green: Administer standard doses	Administer standard doses	Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily when used with rifampin
6025	Efavirenz RTV 410	Efavirenz	600 mg x 10 days	Efavirenz AUC increased 21%; Cmax no significant change	Ritonavir	500 mg Q12H x 8 days	Ritonavir AUC increased 18% after AM dose; Cmax increased 24% after AM dose; AUC no significant change after PM dose; Cmax no significant change after PM dose	Increased efavirenz and ritonavir effects	Green: Administer standard doses	Administer standard doses
6041	Efavirenz Medroxyprogesterone acetate 426	Efavirenz		Efavirenz AUC no significant change	Medroxyprogesterone acetate	150 mg	Progesterone levels: no significant change		Green: Administer standard doses	Administer standard doses
6057	Efavirenz Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide 442	Efavirenz		Not studied (may decrease elvitegravir and cobicistat levels)	Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide		Not studied	Potentially decreased or increased elvitegravir, cobicistat and / or efavirenz effects	Red: Avoid combination	Do not coadminister: Potential for reduced levels of elvitegravir / cobicistat	Use alternative agents
6073	Efavirenz Etonogestrel 458	Efavirenz			Etonogestrel		Etonogestrel decreased 61%	Decreased effects of etonogestrel	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Use alternative contraceptive method
6089	Efavirenz Atovaquone 474	Efavirenz	600 mg QHS		Atovaquone	250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43%	Potentially compromised antimalarial activity	Orange: Minimal data to guide interaction	Consider using alternative agents	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
6105	Efavirenz Posaconazole 490	Efavirenz	400 mg daily	No significant change	Posaconazole	400 mg BID	Posaconazole AUC decreased 50%; Cmax decreased 45%	Decreased posaconazole effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider using alternative agents. If coadministering, dose adjustment has not been established
6121	Efavirenz CBZ 506	Efavirenz	600 mg daily x 35 days	EFV auc decreased 36%, Cmax decreased 21%, Cmin decreased 47%	Carbamazepine	200 mg daily x 3 days, 200 mg BID x 3 days, 400 mg daily for 15 days		Decreased efavirenz and carbamazepine effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Use alternative agents. If coadministering, monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
5978	Efavirenz MVC 363	Efavirenz	600 mg daily		Maraviroc	100 mg BID	Maraviroc AUC decreased 45%; Cmax decreased 51%; Cmin decreased 45%	Decreased maraviroc effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Increase maraviroc dose to 600 mg BID
5994	Efavirenz Voriconazole 379	Efavirenz	300 mg QHS x 7 days	No significant change	Voriconazole	300 mg Q12H on days 2-7	Voriconazole AUC decreased 55%; Cmax decreased 36% (compared to voriconazole 200 mg BID)	Decreased voriconazole effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
6010	Efavirenz RIF 395	Efavirenz	600 mg x 7 days	Efavirenz AUC decreased 26%; Cmax decreased 20%, Cmin decreased 32%	Rifampin	600 mg x 7 days		Decreased efavirenz effects	Green: Administer standard doses	Administer standard doses	Monitor for antiviral efficacy. May consider increasing efavirenz to 800 mg daily when used with rifampin
6026	Efavirenz Prednisolone 411	Efavirenz	not stated		Prednisolone	20 mg x 1	Prednisolone AUC decreased 21%	Potential for increased prednisolone effects (adrenal insufficiency, Cushing?s syndrome).	Green: Administer standard doses	Administer standard doses
6042	Efavirenz SOF 427	Efavirenz	600 mg with emtricitaine 200 mg and tenofovir disoproxil fumarate 300 mg x 1		Sofosbuvir	400 mg x 1	Sofosbuvir Cmax decreased 19%		Green: Administer standard doses	Administer standard doses
6058	Efavirenz CBZ 443	Efavirenz	600 mg daily on days 1-35	Efavirenz AUC decreased 36%; Cmax decreased 21%; Cmin decreased 47%	Carbamazepine	200 mg daily on days 1-3, 200 mg BID on days 4-6, 400 mg daily thereafter	Carbamazepine AUC decreased 27%; Cmax decreased 20%; Cmin decreased 35%	Decreased efavirenz and carbamazepine levels	Red: Avoid combination	Do not coadminister: Reduced levels of carbamazepine and efavirenz	Avoid combination and use alternative agents. If coadministering monitor carbamazepine levels and adjust as indicated. Monitor antiviral efficacy
6074	Efavirenz Etonogestrel 459	Efavirenz			Etonogestrel		Etonogestrel decreased 61%	Decreased effects of etonogestrel	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Use alternative contraceptive method
6090	Efavirenz Atovaquone 475	Efavirenz			Atovaquone	250 mg with 100 mg proguanil x 1	Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43%	Potentially compromised antimalarial activity	Orange: Minimal data to guide interaction	Consider using alternative agents	If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy.
6106	Efavirenz Posaconazole 491	Efavirenz	400 mg BID x 10 and 20 days	No significant change	Posaconazole	400 mg BID for 10 and 20 days	Posaconazole AUC decreased 50%; Cmax decreased 45%	Decreased posaconazole effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider using alternative agents. If coadministering, dose adjustment has not been established
6122	Efavirenz CsA 507	Efavirenz			Cyclosporine			decreased effects of immunosuppresant	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	if co administiring, monitor immunosuppressant efficacy
5979	Efavirenz MVC 364	Efavirenz	600 mg daily		Maraviroc	100 mg BID	Maraviroc AUC decreased 45%; Cmax decreased 51%; Cmin decreased 45%	Decreased maraviroc effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Increase maraviroc dose to 600 mg BID
5995	Efavirenz Voriconazole 380	Efavirenz	300 mg QHS x 7 days	No significant change	Voriconazole	300 mg Q12H on days 2-7	Voriconazole AUC decreased 55%; Cmax decreased 36% (compared to voriconazole 200 mg BID)	Decreased voriconazole effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
6011	Efavirenz DRV 396	Efavirenz	600 mg daily	Efavirenz AUC increased 21%; Cmin increased 17%	Darunavir	300 mg BID with ritonavir 100 mg BID	Darunavir Cmin decreased 31%; Cmax decreased 15%; AUC decreased 13%	Potential for increased efavirenz effects	Green: Administer standard doses	Administer standard doses	Monitor for increased risk of efavirenz related side effects. Consider monitoring drug levels
6027	Efavirenz RAL 412	Efavirenz	600 mg x 14 days		Raltegravir	400 mg x 1	Raltegravir AUC decreased 36%; Cmin decreased 21%; Cmax decreased 36%		Green: Administer standard doses	Administer standard doses
6043	Efavirenz Aluminum and magnesium hydroxide antacid 428	Efavirenz	400 mg x 1 dose	No significant change	Aluminum and magnesium hydroxide antacid	30 mL x 1 dose			Green: Administer standard doses	Administer standard doses
6059	Efavirenz Cariprazine 444	Efavirenz			Cariprazine			Decreased cariprazine levels	Red: Avoid combination	Do not coadminister: Reduced levels of cariprazine	Avoid combination and use alternative agents
6075	Efavirenz Etonogestrel 460	Efavirenz			Etonogestrel			Decreased effects of etonogestrel	Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Use alternative contraceptive method
6091	Efavirenz Itraconazole 476	Efavirenz	600 mg x 14 days	No significant change	Itraconazole	200 mg Q12H x 28 days	Itraconazole AUC decreased 39%; Cmax decreased 37%; Cmin decreased 44%; Hydroxyitraconazole AUC decreased 37%; Cmax decreased 35%; Cmin decreased 43%	Decreased itraconazole effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents
6107	Efavirenz Posaconazole 492	Efavirenz	400 mg daily x 10 and 20 days		Posaconazole	400 mg BID x 10 and 20 days	Posaconazole AUC decreased 50%; Cmax decreased 45%	Decreased posaconazole effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider using alternative agents. If coadministering, dose adjustment has not been established
6123	Efavirenz CsA 508	Efavirenz			Cyclosporine			decreased effects of immunosuppresant	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	if co administiring, monitor immunosuppressant efficacy
5980	Efavirenz Methadone 365	Efavirenz	600 mg x 14-21 days		Methadone	35-100 mg daily	Methadone AUC decreased 52%; Cmax decreased 45%	Decreased methadone effects (eg, withdrawal)	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose. In one study patients required mean dose increase of 30% over period of 60 weeks.
5996	Efavirenz Voriconazole 381	Efavirenz	300 mg x 7 days	No significant change	Voriconazole	300 mg Q12H on days 2-7	Voriconazole AUC decreased 55%; Cmax decreased 36% (compared to voriconazole 200 mg BID)	Decreased voriconazole effects	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of voriconazole and increased levels of efavirenz	Increase voriconazole to 400 mg Q12H and decrease efavirenz to 300 mg QHS
6012	Efavirenz Isavuconazole 397	Efavirenz			Isavuconazole			Possible decreased Isavuconazole levels	Green: Administer standard doses	Administer standard doses	monitor for isravucanazole concentrations and anti fungal response
6028	Efavirenz Fluconazole 413	Efavirenz	400 mg x 7 days	AUC increased 16%; Cmax no significant change	Fluconazole	200 mg x 7 days	No significant change		Green: Administer standard doses	Administer standard doses
6044	Efavirenz AZT, ZDV 429	Efavirenz	600 mg daily x 14 days	No significant change	Zidovudine	300 mg Q12h x 14 days			Green: Administer standard doses	Administer standard doses
6060	Efavirenz EBR/GZR 445	Efavirenz	600 mg daily x 14 days		Elbasvir / Grazoprevir	Elbasvir 50 mg daily with grazoprevir 100 mg daily	Elbasvir AUC decreased 54% Grazoprevir AUC decreased 83%	decreased of elbasvir / grazoprevir effects	Red: Avoid combination	Do not coadminister: Reduced levels of elbasvir / grazoprevir	Contraindicated. Use alternative agents.
6076	Efavirenz Ethinyl estradiol / Norethindrone acetate 461	Efavirenz	400 mg x 10 days	No significant change	Ethinyl estradiol / Norethindrone acetate	Ethinyl estradiol 50 mcg x 1 dose	No significant change		Red: Avoid combination	Do not coadminister: Reduced levels of progestin	Use alternative contraceptive method
6092	Efavirenz Itraconazole 477	Efavirenz	600 mg x 14 days		Itraconazole	200 mg Q12H x 28 days	Itraconazole AUC decreased 39%; Cmax decreased 37%; Cmin decreased 44%; Hydroxyitraconazole AUC decreased 37%; Cmax decreased 35%; Cmin decreased 43%	Decreased itraconazole effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Avoid combination and use alternative agents
6108	Efavirenz Proguanil 493	Efavirenz	400 mg daily		Proguanil	300 mg x 1	Proguanil AUC increased 113%; Cmax increased 47%; Cycloguanil AUC decreased 38%; Cmax decreased 31%	Potential decreased antimalarial effects	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Consider using alternative agents. If coadministering, dose adjustment not established
6124	Efavirenz CsA 509	Efavirenz			Cyclosporine			decreased effects of immunosuppresant	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits when using this combination	if co administiring, monitor immunosuppressant efficacy